User:Mr. Ibrahem/Nimodipine

From Wikipedia, the free encyclopedia

Mr. Ibrahem/Nimodipine
Clinical data
Trade namesNimotop, Nymalize, others
AHFS/Drugs.comMonograph
MedlinePlusa689010
License data
Pregnancy
category
Routes of
administration		Intravenous, by mouth
Drug classCalcium channel blocker (dihydropyridine)
Legal status
Legal status
Pharmacokinetic data
Bioavailability13% (by mouth)
Protein binding95%
MetabolismLiver
Onset of actionRapid[2]
Elimination half-life8–9 hours
Duration of action4 hrs[2]
ExcretionFeces and Urine
Identifiers
  • 3-(2-Methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Chemical and physical data
FormulaC21H26N2O7
Molar mass418.446 g·mol−1
3D model (JSmol)
Melting point7 °C (45 °F)
  • O=C(OC(C)C)\C1=C(\N/C(=C(/C(=O)OCCOC)C1c2cccc([N+]([O-])=O)c2)C)C
  • InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3 checkY
  • Key:UIAGMCDKSXEBJQ-UHFFFAOYSA-N checkY
  (verify)

Nimodipine, sold under the brand name Nimotop among others, is a medication used to prevent vasospasm secondary to subarachnoid hemorrhage.[3] It is taken by mouth or by injection into a vein.[3][4] Onset is rapid with a duration of action of 4 hours.[2]

Common side effects include low blood pressure and headache.[3] Other side effects may include slow heart rate, ileus, and low platelets.[4] Safety in pregnancy is unclear.[5] It is a calcium channel blocker of the dihydropyridine type.[3]

Nimodipine was patented in 1971 and approved for medical use in Germany in 1985.[6][7] It was approved in the United States in 1988.[3] In the United Kingdom 100 tablets of 30 mg costs the NHS about £40.[4] This amount in the United States costs about 170 USD.[8]

References[edit]

  1. ^ a b "Nimodipine Use During Pregnancy". Drugs.com. March 15, 2019. Archived from the original on September 21, 2021. Retrieved April 11, 2020.
  2. ^ a b c Frishman, William H.; Cheng-Lai, Angela; Chen, Julie (June 29, 2013). Current Cardiovascular Drugs. Springer Science & Business Media. p. 161. ISBN 978-1-4615-6767-7. Archived from the original on November 13, 2021. Retrieved November 13, 2021.
  3. ^ a b c d e f g h "Nimodipine Monograph for Professionals". Drugs.com. Archived from the original on September 21, 2021. Retrieved November 13, 2021.
  4. ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 124. ISBN 978-0857114105.
  5. ^ "Nimodipine Use During Pregnancy". Drugs.com. Archived from the original on September 21, 2021. Retrieved November 13, 2021.
  6. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 464. ISBN 9783527607495. Archived from the original on August 29, 2021. Retrieved October 15, 2021.
  7. ^ Bayer AG of Germany (April 10, 1971). "New molecular entity with antihypertensive properties" (Patent (Post-Approval)). UK Patent Office / EspaceNet Patent Search. British patent 1,358,951: Patent Office of the United Kingdom. p. GB1358951. Archived from the original on November 12, 2020. Retrieved April 11, 2019. Priority date: 1971-04-10 (...) Date issued: 1974-07-03{{cite web}}: CS1 maint: location (link)
  8. ^ "Nimodipine Prices and Nimodipine Coupons - GoodRx". GoodRx. Retrieved November 13, 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Nimodipine&oldid=1173401339"